Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Esflurbiprofen transdermal - Taisho Pharmaceutical

Drug Profile

Esflurbiprofen transdermal - Taisho Pharmaceutical

Alternative Names: LOQOA Tape; S-Flurbiprofen; SFPP; TT-063

Latest Information Update: 03 Dec 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Tokuhon Corporation
  • Developer Taisho Pharmaceutical; Tokuhon Corporation
  • Class Analgesics; Antirheumatics; Nonsteroidal anti-inflammatories; Propionic acids
  • Mechanism of Action Cyclo-oxygenase 1 inhibitors; Cyclo-oxygenase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Inflammation; Pain
  • No development reported Muscle pain; Periarthritis

Most Recent Events

  • 20 Nov 2018 Teijin Pharma Corporation, Taisho Toyama Pharmaceutical and Hirosaki University Graduate School of Medicine initiate a clinical trial in Pain (In adults, In the elderly) in Japan (Topical) (UMIN000029709)
  • 09 Nov 2018 Taisho Toyama Pharmaceutical and Tokyo Medical and Dental University complete a clinical trial in Osteoarthritis in Japan (UMIN000024789)
  • 15 Feb 2018 Taisho Pharmaceutical plans a phase III trial for Osteoarthritis in February 2018 , (NCT03434197)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top